IQVIA HOLDINGS INC

IQVIA Holdings’ strategy to grow high‑margin generics, oncology and peptide therapeutics, backed by a strong cash position, fuels optimistic earnings and shareholder value growth.

How Aurobindo Pharma’s FDA approval for Perampanel could capture a share of the $2.6B U.S. seizure‑control market, beat Biogen’s patent cliff, and boost profits.

IQVIA’s award‑winning analytics and patient‑support tech drives cost savings, quality gains, and value‑based care for payors and health systems.

Global healthcare firms are pivoting to tech‑driven consolidation, data analytics, and localized supply chains to beat reimbursement pressures and boost margins by 20 %.

IQVIA leads the AI‑enabled clinical‑trial boom, cutting enrollment time and costs while boosting data quality and payer approval with its cutting‑edge DVT and RWE solutions.

IQVIA strengthens its role in the fast‑growing patient‑experience tech market, offering AI‑powered, integrated solutions that drive engagement, compliance, and higher margins.

IQVIA’s data‑analytics powerhouse delivers 12% revenue growth, 24% EBITDA margin, and AI‑driven insights that help pharma navigate pricing, supply‑chain risk, and value‑based reimbursement.

IQVIA Holdings’ $42B market cap shows why it remains a key player in biopharma data services—offering global reach, AI‑driven analytics, and resilient CRO solutions amid evolving regulations and digital health shifts.

IQVIA’s FY2026 results reveal disciplined cost cuts and a strategic shift to high‑margin, value‑based APIs, positioning it for long‑term growth despite commodity headwinds.

IQVIA’s 2026 H1 biosimilar surge lifts net sales 5.6% and EBITDA over 20%, driven by North America, digital‑health bundling, and supply‑chain resilience.